Cargando…

Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study

INTRODUCTION: Two risk minimization (RM) tools—a healthcare professional frequently asked questions (HCP-FAQs) brochure and a patient/caregiver information brochure (PCIB)—were developed for HCPs and for adolescents (aged ≥ 13 years) receiving aripiprazole for bipolar I mania and their caregivers. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landsberg, Wally, Al-Dakkak, Imad, Coppin-Renz, Antonia, Geis, Uli, Peters-Strickland, Timothy, van Heumen, Emiel, Rahman, Mirza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061424/ https://www.ncbi.nlm.nih.gov/pubmed/29671224 http://dx.doi.org/10.1007/s40264-018-0662-2

Ejemplares similares

Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania
por: Ostacher, Michael J, et al.
Publicado: (2015)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert, Marc, et al.
Publicado: (2015)

Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
por: Patel, Hina, et al.
Publicado: (2021)

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia
por: Cochran, Jeffrey M, et al.
Publicado: (2022)

Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe
por: Mayall, Steve, et al.
Publicado: (2021)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland, Timothy, et al.
Publicado: (2019)

Addition of Aripiprazole to the Clozapine May Be Useful in Reducing Anxiety in Treatment-Resistant Schizophrenia
por: Chanachev, Aleksandar, et al.
Publicado: (2011)

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug
por: Rohde, Morten, et al.
Publicado: (2014)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
por: Kawai, Akito, et al.
Publicado: (2022)

PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
por: Peters-Strickland, Timothy, et al.
Publicado: (2016)

Aripiprazole cardiosafety: Is it overestimated?
por: Naguy, Ahmed
Publicado: (2016)

Aripiprazole-induced priapism
por: Trivedi, Satya K., et al.
Publicado: (2016)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Authors' Response to Letter to the Editor. Fake Union
por: Oba, Hiroki, et al.
Publicado: (2023)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel
por: Veznedaroglu, Baybars, et al.
Publicado: (2018)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Tardive Dyskinesia: Treatment with Aripiprazole
por: Kang, Na-Ri, et al.
Publicado: (2011)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Aripiprazole-induced skin rash
por: Nath, Santanu, et al.
Publicado: (2016)

Tardive Dystonia Related with Aripiprazole
por: Kim, Sunghwan, et al.
Publicado: (2017)

Aripiprazole-induced transient myopia
por: Cumurcu, Tongabay, et al.
Publicado: (2019)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

The work of the European Union Reference Laboratory for Food Additives (EURL) and its support for the authorisation process of feed additives in the European Union: a review
por: von Holst, Christoph, et al.
Publicado: (2016)

A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness
por: Kopelowicz, Alex, et al.
Publicado: (2017)

Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome
por: Gerasch, Sarah, et al.
Publicado: (2016)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

Aripiprazole monotherapy in an adolescent worsens psychosis
por: Panigrahi, Mahima, et al.
Publicado: (2013)

Aripiprazole for acute mania in an elderly person
por: Bharadwaj, Balaji, et al.
Publicado: (2011)

Worsened hypertension control induced by aripiprazole
por: Yasui-Furukori, Norio, et al.
Publicado: (2013)

In vivo anti-Toxoplasma activity of aripiprazole
por: Saraei, Mehrzad, et al.
Publicado: (2015)

Aripiprazole reduces liver cell division
por: Pirc Marolt, Tinkara, et al.
Publicado: (2020)

Aripiprazole-induced obsessive–compulsive symptoms
por: Nafisa, Dilshana, et al.
Publicado: (2022)

Aripiprazol and Hypersexuality: when partial is to much
por: Espada-Santos, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9bjq3rs6870e8470tdnje275e5